CD19[FITC], His, Human
¥9900 | |
Z04145-100 | |
|
|
|
|
|
¥9900 | |
Z04145-100 | |
|
|
|
|
|
Species | Human | ||||
Protein Construction |
|
||||
Conjugate | FITC | ||||
Purity |
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC |
||||
Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
Expression System | HEK293 | ||||
Theoretical Molecular Weight | 60.1 kDa | ||||
Apparent Molecular Weight | Due to glycosylation, the protein migrates to 68-72 kDa based on Bis-Tris PAGE result. | ||||
Formulation | Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4). | ||||
Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of CD19[FITC], His, Human is greater than 95% as determined by SEC-HPLC. »
CD19[FITC], His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
Immobilized CD19[FITC], His, Human, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-CD19 Antibody, hFc Tag with the EC50 of 9.3 ng/ml determined by ELISA. »
FACS Analysis of Anti-CD19 CAR expression. 293T cells were transfected with anti-CD19-scFv and His tag. Cells were incubated with 10 μg/ml CD19[FITC], His, Human, His Tag and FITC-labeled protein control. Non-transfected 293T cells and FITC-labeled protein control were used as negative control. »
Target Background | CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging. |
Synonyms | CD19; B4; CVID3; Leu-12; MGC12802 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.